Ani Pharmaceuticals (ANIP) Asset Writedowns and Impairment (2010 - 2024)
Ani Pharmaceuticals (ANIP) posted Asset Writedowns and Impairment of $7.6 million for Q4 2024, up 760100.0% sequentially from -$1000.0 in Q3 2022.
Ani Pharmaceuticals (ANIP) Asset Writedowns and Impairment (2010 - 2024) Analysis & Trends
Ani Pharmaceuticals has reported Asset Writedowns and Impairment for 6 years, with the latest figure at $7.6 million in Q4 2024.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $7.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $7.6 million (changed 0.0% YoY) and the FY2025 annual result came in at $767000.0, down 89.91% from the prior year.
- Asset Writedowns and Impairment improved to $7.6 million in Q4 2024 per ANIP's latest filing, from -$1000.0 in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $7.6 million in Q4 2024 and troughed at -$1000.0 in Q3 2022.
- A 4-year average of $2.1 million and a median of $341000.0 in 2020 frame the typical range for Asset Writedowns and Impairment.
- The sharpest annual moves came in 2020 and 2021: Asset Writedowns and Impairment surged 354.67% in 2020, then surged 596.19% in 2021.
- Over 4 years, Asset Writedowns and Impairment stood at $341000.0 in 2020, then soared by 596.19% to $2.4 million in 2021, then tumbled by 100.04% to -$1000.0 in 2022, then soared by 760100.0% to $7.6 million in 2024.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $7.6 million, -$1000.0, and $2.4 million for Q4 2024, Q3 2022, and Q4 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.28 Bn | 165.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 7.60 Mn |
| Dec 31, 2024 | 7.60 Mn |
| Sep 30, 2022 | -1,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Dec 31, 2021 | 2.37 Mn |
| Dec 31, 2021 | 2.37 Mn |
| Dec 31, 2020 | 341,000.00 |
| Dec 31, 2020 | 341,000.00 |
| Sep 30, 2020 | 100,000.00 |
| Sep 30, 2020 | 100,000.00 |
| Dec 31, 2019 | 75,000.00 |
| Dec 31, 2019 | 75,000.00 |
| Sep 30, 2010 | 286,000.00 |
| Sep 30, 2010 | 286,000.00 |